Severe Organizing Pneumonia after Two Cycles of Docetaxel as Fourth-Line Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung

被引:5
|
作者
Hasskarl, Jens [1 ]
Schroettner, Percy [1 ]
Den Berg, Andrea Von [1 ]
Rueckert, Anja [1 ]
Frydrychowicz, Alex [2 ]
Kayser, Gian [3 ]
Waller, Cornelius F. [1 ]
机构
[1] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Freiburg, Germany
[2] Univ Hosp Freiburg, Dept Diagnost Radiol Med Phys, Freiburg, Germany
[3] Freiburg Med Sch, Inst Pathol, Freiburg, Germany
来源
CASE REPORTS IN ONCOLOGY | 2009年 / 2卷 / 01期
关键词
Docetaxel; Taxane; Bronchiolitis obliterans organizing pneumonia; BOOP; Organizing pneumonia; OP;
D O I
10.1159/000200015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Organizing pneumonia (formerly known as bronchiolitis obliterans organizing pneumonia, BOOP) is an inflammatory process of the bronchioles that can lead to the destruction of small airways and surrounding lung tissue. Although the majority of cases are idiopathic, certain chemicals and drugs can induce OP. Here, we report a 54-year-old male patient with advanced non-small cell lung cancer (NSCLC) who developed therapy-associated OP. He had undergone several other chemotherapies before being switched to docetaxel as monotherapy (75 mg/m(2)). Treatment was initially well tolerated, but after the second cycle the patient developed increasing shortness of breath. Computed tomography (CT) for staging after the second cycle showed bilateral predominantly interstitial infiltration highly suggestive of acute lung fibrosis. Bronchoscopy revealed signs of chronic bronchitis and watery discharge from both lungs. Bronchoalveolar lavage and transbronchial needle biopsy was performed. Based on histopathologic examination, diagnosis of OP was made. After cessation of docetaxel and initial high dose steroids, the infiltration ameliorated rapidly. This is the second case in the literature that associates docetaxel with rapid onset of bronchiolitis obliterans. Therefore, patients with lung cancer receiving docetaxel who develop respiratory symptoms should be suspected to develop OP.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 50 条
  • [1] Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi, Yong Won
    Ahn, Mi Sun
    Jeong, Geum Sook
    Lee, Hyun Woo
    Jeong, Seong Hyun
    Kang, Seok Yun
    Park, Joon Seong
    Choi, Jin-Hyuk
    Lee, Soon Young
    LUNG CANCER, 2015, 87 (02) : 155 - 161
  • [2] Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
    Asahina, Hajime
    Sekine, Ikuo
    Horinouchi, Hidehito
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Kubota, Kaoru
    Tamura, Tomohide
    CLINICAL LUNG CANCER, 2012, 13 (01) : 39 - 43
  • [3] Advanced Non-Small Cell Lung Carcinoma: The Emerging Role of Docetaxel
    Corey J. Langer
    Investigational New Drugs, 2000, 18 : 17 - 28
  • [4] Advanced non-small cell lung carcinoma: The emerging role of docetaxel
    Langer, CJ
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 17 - 28
  • [5] Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel
    Matsuoka M.
    Boku N.
    Yoshino T.
    Hironaka S.
    Onozawa Y.
    Fukutomi A.
    Zenda S.
    Yamazaki K.
    Yasui H.
    Hasuike N.
    Inui T.
    Yamaguchi Y.
    Ono H.
    Kamata M.
    International Journal of Clinical Oncology, 2005, 10 (6) : 429 - 432
  • [6] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel
    Belani, CP
    LUNG CANCER, 2005, 50 : S3 - S8
  • [8] Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
    W. Schuette
    I. Bork
    B. Wollschläger
    S. Schädlich
    Clinical Drug Investigation, 2001, 21 : 161 - 168
  • [9] Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer
    Schuette, W
    Bork, I
    Wollschläger, B
    Schädlich, S
    CLINICAL DRUG INVESTIGATION, 2001, 21 (03) : 161 - 168
  • [10] PHASE II STUDY OF AMRUBICIN FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: UPDATED RESULTS
    Oizumi, Satoshi
    Harada, Toshiyuki
    Ito, Kenichiro
    Takamura, Kei
    Kuda, Tomoya
    Sugawara, Shunichi
    Watanabe, Kana
    Maemondo, Makoto
    Fujita, Yuka
    Kinoshita, Ichiro
    Inoue, Akira
    Hommura, Fumihiro
    Katsuura, Yutaka
    Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    RESPIROLOGY, 2013, 18 : 8 - 8